Richard Sheng Poe Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard Sheng Poe Huang has a total of 451 co-authors. Here are the top co-authors by number of shared publications:
- Emanuel Gonçalves
Instituto Superior Técnico (IST), Universidade de Lisboa, Lisboa, Portugal
48 shared publications - Isabel Fernandes
13Medical Oncology Department, Hospital CUF Descobertas, Lisboa, Portugal
48 shared publications - Luís Costa
Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte, Avenida Professor Egas Moniz MB, 1649-028 Lisboa, Portugal
48 shared publications - Manuel Sokolov Ravasqueira
Instituto de Engenharia de Sistemas e Computadores – Investigação e Desenvolvimento (INESC-ID), Lisboa, Portugal
48 shared publications - Miguel Esperança-Martins
Medical Oncology Department, Unidade Local de Saúde de Santa Maria, Lisboa, Portugal
48 shared publications - Nuno Abecasis
Instituto Português de Oncologia de Lisboa Francisco Gentil
48 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Springer Nature in npj Precision Oncology
Landscape and clinical impact of heterogeneous ALK resistance mutations detected by comprehensive genomic profiling in patients with NSCLC
- 29 October 2026
- Published by Springer Nature in npj Precision Oncology
Open AccessLandscape and clinical impact of heterogeneous ALK resistance mutations detected by comprehensive genomic profiling in patients with NSCLC
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
PHAROS study design and participants, clinical validation, and F1CDx analyses
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
PHAROS study design and participants, clinical validation, and F1CDx analyses
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S6. Summary statistics of F1LCDx test PPA and PPV after including imputed data
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S6. Summary statistics of F1LCDx test PPA and PPV after including imputed data
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
PHAROS study design and participants, clinical validation, and F1CDx analyses
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
PHAROS study design and participants, clinical validation, and F1CDx analyses
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S7. Summary statistics of ORR for the F1LCDx+/CTA+ population (ƍ1) on imputed complete data
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S7. Summary statistics of ORR for the F1LCDx+/CTA+ population (ƍ1) on imputed complete data
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S4. Contingency table comparing BRAF V600E status between the CTA and F1CDx
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S4. Contingency table comparing BRAF V600E status between the CTA and F1CDx
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S7. Summary statistics of ORR for the F1LCDx+/CTA+ population (ƍ1) on imputed complete data
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S7. Summary statistics of ORR for the F1LCDx+/CTA+ population (ƍ1) on imputed complete data
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S3. Concordance analysis results between CTA and F1LCDx tests
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S3. Concordance analysis results between CTA and F1LCDx tests
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S1. Demographics and clinical characteristics in the F1CDx-evaluable and -unevaluable populations
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S1. Demographics and clinical characteristics in the F1CDx-evaluable and -unevaluable populations
- Open Access
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S5. Primary efficacy in the F1CDx test subpopulations
- 29 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non–Small Cell Lung Cancers from the PHAROS Study
Table S5. Primary efficacy in the F1CDx test subpopulations